Patient Satisfaction and Quality of Life Impact - PecFent®

A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

Inclusion Criteria:

• Adult (aged ≥18 years) with cancer
• Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain